PCMA: DIR Legislation Would Increase Premiums, Medicare Part D Costs

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on H.R. 1038, legislation introduced by Reps. Morgan Griffith (R-VA) and Peter Welch (D-VT), that would prohibit Medicare Part D plans from using direct and indirect remuneration (DIR) for pharmacies in Part...

Read More

PCMA Releases New Video: “What is Drug Price Transparency?”

(Washington, D.C.) — As part of its DrugBenefitSolutions.com campaign, the Pharmaceutical Care Management Association (PCMA) today released a new video, “What is drug price transparency?” explaining how transparency is widely used in the prescription drug marketplace for patients and employers, and highlighting that “the wrong...

Read More

PCMA Statement on New Class-Action Lawsuit Against Drug Companies

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on today’s new class-action lawsuit against three makers of insulin drug products: “While we’re still reviewing the details of the lawsuit – in which pharmacy benefit managers (PBMs) are not named as...

Read More

PCMA Statement on Gov. Cuomo’s NY Prescription Drug Price Proposal

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new proposal by Governor Andrew Cuomo (D-NY) that includes regulations on pharmacy benefit managers (PBMs): “This mandate would increase costs by tying the hands of employers, unions, and public programs...

Read More

New Research: PBMs Save $941 Per Person Annually

(Washington, D.C.) — Pharmacy benefit managers (PBMs) are saving consumers and payers an average of $941 per person per year, according to a new analysis by Visante. The new research also highlights PBMs’ role in reducing medication errors and improving the lives of patients through...

Read More

PCMA Offers Policy Recommendations to Stem Rx Abuse, Reduce Costs

(Washington, D.C.) —Testifying before the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law, Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt offered policy recommendations to help stem the rising tide of drug abuse and reduce costs at the hearing, Treating the...

Read More

PCMA Statement on Oversight Committee Hearing on EpiPen Price Hikes

(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on today’s House Committee on Oversight and Government Reform hearing, “Reviewing the Rising Price of EpiPens:” “For EpiPens, price concessions negotiated by pharmacy benefit managers (PBMs) have significantly reduced...

Read More

Survey on Drug Costs: Employers Prefer Private Sector Solutions

(Washington, D.C.) — America’s employers are concerned about high drug prices and think private sector solutions would address the issue more effectively than government intervention, according to a national survey from North Star Opinion Research released by the Pharmaceutical Care Management Association (PCMA). By a...

Read More

PCMA on New PwC Report: PBMs Driving Competition to Reduce Drug Costs

June 21, 2016 (Washington, D.C.) — The new PwC Health Research Institute (HRI) annual report (“Medical Cost Trend: Behind the Numbers 2017”) highlights how pharmacy benefit managers (PBMs) help reduce drug cost trend, specifically noting that: “With increased appetite from employers to narrow their formularies...

Read More

PCMA Launches Second Phase of “That’s What PBMs Do” Campaign

June 13, 2016 Campaign Highlights How Specialty and Preferred Pharmacy Networks Help Patients, Reduce Costs (Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today launched the second phase of its That’s What PBMs Do campaign with two new videos explaining how specialty pharmacies and...

Read More

PBM Policy Forum 2016

The PCMA PBM Policy Forum was hosted April 11, 2016 in Washington, DC. The forum, focused on the cost of prescription drugs and the latest efforts to bring those costs down, brought together healthcare and drug industry advocates from think tanks, patient advocacy groups, and...

Read More

PCMA Statement on the FDA’s Decision to Approve the Second U.S. Biosimilar

April 6, 2016 Increased Competition Lowers Drug Costs (Washington, D.C.)—Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on yesterday’s decision by the Food and Drug Administration (FDA) to approve Inflectra, the second biosimilar approved in the United States. Inflectra...

Read More

PCMA Launches New Campaign: ‘That’s What PBMs Do’

March 17, 2016 Campaign shows how PBMs reduce costs, improve pharmacy benefits, and features new national and state-specific savings data, video, and ads (Washington D.C.)— As policymakers seek solutions to combat high drug prices, the Pharmaceutical Care Management Association (PCMA) is launching a new national...

Read More

PBMs Provide Policy Solutions to Increase Competition, Reduce Rx Costs

February 4, 2016 (Washington, D.C.)— Testifying before the House Committee on Oversight and Government Reform, Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt outlined market-based policy solutions to help increase competition and lower prescription drug costs. The Committee is examining “methods and reasoning...

Read More

PCMA: Increase Competition to Reduce Prescription Drug Costs

November 20, 2015 (Washington D.C.)— Stakeholders at today’s Health and Human Services (HHS) Pharmaceutical Forum should examine ways to increase competition and eliminate delays in drug approvals that would in turn lower costs and improve patient access, the Pharmaceutical Care Management Association (PCMA) said. “The...

Read More

New Pharmacy Mandates Would Increase Rx Costs, Undermine Competition

November 17, 2015 (Washington D.C.)—As the House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law examines competition “in the pharmacy benefit managers and pharmacy marketplaces,” policymakers should examine how greater use of pharmacy benefit management tools lower prescription drug costs, enhances access and improves...

Read More

PCMA Outlines 2015 Policy Agenda

January 21, 2015 Promote Lower Cost Pharmacy Options, Increase Competition, Reduce Health Care Fraud, Waste, and Abuse (Washington D.C.)—The Pharmaceutical Care Management Association (PCMA) today released its 2015 policy agenda, which includes reducing prescription drug costs for consumers, employers, unions, Medicare Part D, and other government...

Read More

PCMA Statement on 21st Century Cures

May 21, 2015 (Washington, D.C.)—The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding the Medicare Part D offsets included in the Energy & Commerce Committee’s 21st Century Cures initiative: “If the 21st Century Cures initiative can only be advanced by cutting billions from...

Read More

325 7th Street, NW, 9th Floor, Washington, DC 20004
(202) 756-5700